New hope for leukemia patients who have run out of options
NCT ID NCT07441980
First seen Mar 08, 2026 · Last updated May 14, 2026 · Updated 12 times
Summary
This early-stage study tests a new treatment called CT1390B for adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and see if it helps control the disease. About 18 participants will receive the treatment and be closely monitored.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, China
Tianjin, China
Conditions
Explore the condition pages connected to this study.